ADARx Pharmaceuticals Targeted $1.74 Billion IPO Valuation
The San Diego-based biotech firm filed for a public listing aiming to raise over $370 million in capital.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you think now is a good time to invest in new biotech company stock offerings?
ADARx Pharmaceuticals has announced plans for a U.S. initial public offering, seeking to raise as much as $371.9 million. The company aims to achieve a valuation of $1.74 billion upon listing on the Nasdaq.
Why it matters
The move reflects a strengthening investor appetite for biotech listings in the current market environment. AbbVie has signaled support for the venture by securing a 4.9% stake through a concurrent private placement.
The firm is offering 21.9 million shares at a projected range of $15 to $17 per share. This pricing targets an overall company valuation of $1.74 billion, supported by AbbVie’s pre-IPO private equity stake.
The players
ADARx Pharmaceuticals
A San Diego-based biotechnology firm focused on developing therapeutics that seek to modulate gene expression.
AbbVie
A global biopharmaceutical company with a diversified portfolio of immunology, oncology, and neuroscience therapies.
The details
ADARx Pharmaceuticals, headquartered in San Diego, is preparing to list its shares on the Nasdaq exchange under the ticker ADRX. The process involves multiple investment banks including JP Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital acting as underwriters. The capital generated is intended to support the company’s operations as it transitions toward public market status.
Timeline
September 21, 2026: ADARx Pharmaceuticals announced its official IPO plans.
The Tech Race
This listing follows the 2024 surge in biotech public offerings, marking a critical transition point for clinical-stage firms seeking liquidity. It signals a move by mid-tier biotech entities to capitalize on rebounding sentiment for R&D-heavy portfolios.
Public markets will be able to trade the company’s shares under the ADRX symbol once the IPO completes. The timing and share price remain subject to final adjustments based on institutional demand during the roadshow period.
The takeaway
The firm’s ability to secure institutional interest via AbbVie provides a significant validation marker for its valuation strategy. Investors should watch for the official pricing announcement from the underwriters to confirm the final market valuation.
Further reading
For more on market trends, visit Biotech.
Live Poll
Do you think now is a good time to invest in new biotech company stock offerings?
